CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Brand sodium ferric gluconate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02399449
NCT02399449Phase 4Completed

Evaluation of Iron Species in Healthy Subjects Treated With Generic and Reference Sodium Ferric Gluconate

University of Maryland, Baltimore·interventional·Posted Mar 26, 2015·Updated Sep 28, 2022

In Brief

A Phase 4 clinical trial evaluating Brand sodium ferric gluconate and Generic sodium ferric gluconate for Anemia. Completed, enrolled 110 participants across 1 site.

Detailed Summary

An approved treatment for anemia or low blood count due to chronic kidney disease is IV (intravenous, given into the vein) injection of an iron treatment. IV iron increases iron in the blood. Many IV iron therapies are now available in both brand name and generic forms. One common IV iron product is sodium ferric gluconate (SFG) sold as brand name Ferrlecit. Recently, a generic version of Ferrlecit was approved but was felt to be possibly more toxic than the brand product. The purpose of this research project is to see if the brand and generic IV iron products produce the same amount of iron in the blood in healthy volunteers, including an iron form that more toxic than other iron forms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 26, 2015
Enrollment StartSep 15, 2017
Primary CompletionMar 22, 2019
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.3 years ago

Interventions

Brand sodium ferric gluconatedrug

brand product

Generic sodium ferric gluconatedrug

generic product